← Back to Clinical Trials
Recruiting NCT06832631

NCT06832631 VITUS Post-Market Registry

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06832631
Status Recruiting
Phase
Sponsor OrbusNeich
Condition Peripheral Arterial Disease
Study Type OBSERVATIONAL
Enrollment 284 participants
Start Date 2025-05-22
Primary Completion 2027-04

Trial Parameters

Condition Peripheral Arterial Disease
Sponsor OrbusNeich
Study Type OBSERVATIONAL
Phase N/A
Enrollment 284
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-05-22
Completion 2027-04
Interventions
Percutaneous Transluminal Angioplasty with a paclitaxel drug-coated balloon

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To collect post marketing surveillance data on consecutive patients with peripheral arterial occlusive disease (PAOD) intended to be or treated by the VITUS peripheral drug-coated dilatation catheter when used according to the Instructions for Use and treating physician decision. Data will be collected in order to assess the long-term safety and performance of the VITUS peripheral drug-coated dilatation catheter in routine clinical practice.

Eligibility Criteria

Inclusion Criteria: * Consecutive patients intended to be or treated by the VITUS peripheral drug-coated dilatation catheter as per physicians' decision and according to IFU in the setting of routine clinical care are entered into the registry * The lesion to be treated should be shorter than the nominal length of balloon at a reference vessel diameter of 2.0 mm up to 7.0 mm. * If lesion is longer than the individual balloon, more than one DCB can be used for longer lesions with the mandatory overlapping balloons of 10mm to avoid any geographical miss. * Rutherford clinical categories 2-5 Exclusion Criteria: * The patients are excluded from registration if ANY of the following conditions apply: * High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons) * Currently participating in another investigational drug or device study in which a routine angiographic follow-up in peripheral arteries is planned * A life expectancy of \<1year

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology